Epilepsy Ireland have been notified by Bus Éireann that they intend to remove Epilepsy Ireland member discounts at the end of the year.
New research from the USA has reported positive findings regarding the use of a Vitamin K based compound in the treatment of drug-resistant epilepsy.
Epilepsy Ireland have published our Annual Report for 2019.
The report offers a review of the activities and services that we carried out throughout 2019 on the behalf of our members, service users, volunteers and supporters as we continue our journey towards a society where no person's life is limited by epilepsy.
For the first times in six months following the onset of COVID-19 in Ireland, this week sees children return physically to schools all across the country. This has led to excitement for children as they meet with their friends and continue their learning in this new environment but also has also led to understandable concerns and nervousness for parents and teachers alike.
A new international survey has been launched by the UCD Centre for Disability Studies seeking to measure the impact of COVID-19 on individuals who have an intellectual and/or developmental disability.
An updated Patient Information Leaflet has been published for women and girls that are taking Sodium Valproate (Epilim).
A study presented at the European Academy of Neurology annual congress has found that mortality rates for epilepsy-related deaths did not decrease between 2009 and 2015 despite advances in treatment during this time.
The study was conducted by Dr. Gashirai Mbizvo from the University of Edinburgh who analysed anonymous data from healthcare settings around Scotland of patients who had died between 2009 & 2015.
A new study published in the Lancet has identified the world's first environmental risk factor for a common form of childhood epilepsy, Benign Childhood Epilepsy with Centro-temporal Spikes (BECTS). BECTS is also known as Benign Rolandic Epilepsy and accounts for about 20% of all childhood epilepsy.